PMID- 19381448
OWN - NLM
STAT- MEDLINE
DCOM- 20091109
LR  - 20220410
IS  - 1573-7373 (Electronic)
IS  - 0167-594X (Linking)
VI  - 94
IP  - 3
DP  - 2009 Sep
TI  - Allostatic tumor-burden induces depression-associated changes in hepatoma-bearing 
      mice.
PG  - 367-72
LID - 10.1007/s11060-009-9887-3 [doi]
AB  - The high incidence of depression among cancer patients has created the need for 
      deeper insights into its underlying pathophysiological mechanism. The aim of the 
      current study is to demonstrate the presence of depressive states due to 
      allostatic tumor-burden in the animal model, and if possible to elucidate the 
      mechanism(s) by which the tumor might induce the depressive state. Stress-related 
      behavioral responses and tumor weight were evaluated 6, 8, and 12 days after 
      implantation of H22 hepatoma cells into the right flank of mice. Brain changes 
      associated with depression were also observed 12 days after tumor implantation. 
      The mice that were subjected to tumor-burden exhibited a significant 
      depression-like state which manifested as behavioral changes including prolonged 
      time spent immobile in the tail suspension test and reduced spontaneous motor 
      activity with tumor progression. These behavior indices changed significantly 12 
      days after tumor implantation and were improved by the antidepressant fluoxetine. 
      Correspondingly, the activity of superoxide dismutase (SOD) in the cerebrum and 
      the expression of glia maturation factor beta (GMF-beta) and brain-derived 
      neurotrophic factor (BDNF) in the hippocampus were significantly decreased in 
      tumor-bearing mice, and these decreases were also reversed by fluoxetine. Taken 
      together, these data indicate that tumor-burden might induce depressive-related 
      behavior and brain changes, and suggest that antidepressants might not only 
      palliate depression symptoms but also modify disease processes in the auxiliary 
      treatment of cancer.
FAU - Qi, Hong
AU  - Qi H
AD  - Department of Pharmacology, Institute of Medical Sciences, Shanghai Jiaotong 
      University School of Medicine, Shanghai, China.
FAU - Ma, Jian
AU  - Ma J
FAU - Liu, Yan-Mei
AU  - Liu YM
FAU - Yang, Lan
AU  - Yang L
FAU - Peng, Liang
AU  - Peng L
FAU - Wang, Hao
AU  - Wang H
FAU - Chen, Hong-Zhuan
AU  - Chen HZ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090421
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Glia Maturation Factor)
RN  - 0 (RNA, Messenger)
RN  - 01K63SUP8D (Fluoxetine)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Antidepressive Agents, Second-Generation/therapeutic use
MH  - Brain-Derived Neurotrophic Factor/genetics/metabolism
MH  - Carcinoma, Hepatocellular/*complications/pathology
MH  - Cerebral Cortex/drug effects/metabolism
MH  - Depression/drug therapy/*etiology/metabolism
MH  - Disease Models, Animal
MH  - Fluoxetine/therapeutic use
MH  - Gene Expression Regulation, Neoplastic/drug effects/physiology
MH  - Glia Maturation Factor/genetics/metabolism
MH  - Hindlimb Suspension/methods
MH  - Hippocampus/drug effects/metabolism
MH  - Liver Neoplasms/*complications/pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Motor Activity/drug effects
MH  - Neoplasm Transplantation
MH  - RNA, Messenger/metabolism
MH  - Superoxide Dismutase/metabolism
MH  - Time Factors
MH  - *Tumor Burden
MH  - Tumor Cells, Cultured
EDAT- 2009/04/22 09:00
MHDA- 2009/11/10 06:00
CRDT- 2009/04/22 09:00
PHST- 2008/06/15 00:00 [received]
PHST- 2009/04/02 00:00 [accepted]
PHST- 2009/04/22 09:00 [entrez]
PHST- 2009/04/22 09:00 [pubmed]
PHST- 2009/11/10 06:00 [medline]
AID - 10.1007/s11060-009-9887-3 [doi]
PST - ppublish
SO  - J Neurooncol. 2009 Sep;94(3):367-72. doi: 10.1007/s11060-009-9887-3. Epub 2009 
      Apr 21.